Nicotinamide phosphoribosyltransferase in human diseases

Journal of Bioanalysis and Biomedicine

Volumn 3, Issue 1, 2011, Pages 13-25

  Zhang, Li Qin ^a   Heruth, Daniel P ^a   Ye, Shui Qing ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokine; Growth factor; NAMPT; PBEF; Visfatin

Indexed keywords

DAPORINAD; FENOFIBRATE; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; LISINOPRIL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROTEIN P53; ROSIGLITAZONE; SIRTUIN 1; SIRTUIN 3; SIRTUIN 4; STAT3 PROTEIN; STROMELYSIN; TELMISARTAN; VALSARTAN;

ACUTE LUNG INJURY; ADENOSINE DIPHOSPHATE RIBOSYLATION; AGING; ATHEROSCLEROSIS; BINDING SITE; CYTOKINE RELEASE; DIABETES MELLITUS; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME STRUCTURE; EXON; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC SCREENING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; INTRON; MOLECULAR DYNAMICS; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE;

EID: 79951968731     PISSN: None     EISSN: 1948593X     Source Type: Journal    
DOI: 10.4172/1948-593X.1000038     Document Type: Review

References (127)

1. Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor. Mol Cell Biol 14: 1431-1437.
2. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, et al. (2001) Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 26: 107-117.
3. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, et al. (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32: 3225-3234.
4. Martin PR, Shea RJ, Mulks MH (2001) Identification of a plasmid-encoded gene from Haemophilus ducreyi which confers NAD independence. J Bacteriol 183: 1168-1174.
5. McGlothlin JR, Gao L, Lavoie T, Simon BA, Easley RB, et al. (2005) Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochem Genet 43: 127-141.
6. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, et al. (2005) Pre-Bcell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 171: 361-370.
7. Bajwa EK, Yu CL, Gong MN, Thompson BT, Christiani DC (2007) Pre-B-cell colony-enhancing factor gene polymorphisms and risk of acute respiratory distress syndrome. Crit Care Med 35: 1290-1295.
8. Johansson LM, Johansson LE, Ridderstråle M (2008) The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects. Metabolism 57: 1558-1562.
9. Tokunaga A, Miura A, Okauchi Y, Segawa K, Fukuhara A, et al. (2008) Thea-1535 promoter variant of the visfatin gene is associated with serum triglyceride and HDL-cholesterol levels in Japanese subjects. Endocr J 55: 205-212.
10. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, et al. (2006) Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 55: 2896-2902.
11. Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, et al. (2006) The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 23: 967-973.
12. Böttcher Y, Teupser D, Enigk B, Berndt J, Klöting N, et al. (2006) Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat-depot-specific messenger ribonucleic acid expression in humans. J Cli Endocrinol Metab 91: 2725-2731.
13. Thierry-Mieg D, Thierry-Mieg J (2006) AceView: a comprehensive cDNAsupported gene and transcripts annotation. Genome Biol 7 S12.
14. Chen H, Xia T, Zhou L, Chen X, Gan L, et al. (2007) Gene organization, alternate splicing and expression pattern of porcine visfatin gene. Domest Anim Endocrinol 32: 235-245.
15. Palin MF, Labrecque B, Beaudry D, Mayhue M, Bordignon V, et al. (2008) Visfatin expression is not associated with adipose tissue abundance in the porcine model. Domest Anim Endocrinol 35: 58-73.
16. Khan JA, Tao X, Tong L (2006) Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13: 582-588.
17. + biosynthetic enzyme. Nat Struct Mol Biol 13: 661-662.
18. Kim MK, Lee JH, Kim H, Park SJ, Kim SH, et al. (2006) Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. J Mol Biol 362: 66-77.
19. +-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 97: 25-34.
20. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430.
21. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2007) Retraction. Science 318: 565.
22. Xie H, Tang SY, Luo XH, Huang J, Cui RR, et al. (2007) Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80: 201-210.
23. Jia SH, Li Y, Parodo J, Kapus A, Fan L, et al. (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113: 1318-1327.
24. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, et al. (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56: 2829-2839.
25. Tilg H, Moschen AR (2008) Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci(Lond) 114: 275-288.
26. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, et al. (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115: 972-980.
27. Ognjanovic S, Bryant-Greenwood GD (2002) Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 187: 1051-1058.
28. Liu P, Li H, Cepeda J, Zhang LQ, Cui X, et al. (2009) Critical role of PBEF expression in pulmonary cell inflammation and permeability. Cell Bio Int 33: 19-30.
29. Li H, Liu P, Cepeda J, Fang D, Easley RB, et al. (2008) Augmentation of Pulmonary Epithelial Cell IL-8 Expression and Permeability by Pre-B-cell Colony Enhancing Factor. J Inflamm (Lond) 5: 15.
30. Hong SB, Huang Y, Moreno-Vinasco L, Sammani S, Moitra J, et al. (2008) Essential role of pre-B-cell colony enhancing factor in ventilator-induced lung injury. Am J Respir Crit Care Med 178: 605-617.
31. Revollo JR, Grimm AA, Imai S (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 279: 50754-50763.
32. van der Veer E, Ho C, O'Neil C, Barbosa N, Scott R, et al. (2007) Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 282: 10841-10845.
33. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, et al. (2007) NAMPT/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363-375.
34. Berger F, Ramirez-Hernandez MH, Ziegler M (2004) The new life of a centenarian: signalling functions of NAD[P]. Trends Biochem Sci 29: 111-118.
35. Ziegler M (2000) New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem 267: 1550-1564.
36. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, et al. (2004) Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380.
37. Corda D, Di Girolamo M (2003) Functional aspects of protein mono-ADPribosylation. EMBO J 22: 1953-1958.
38. Gerth A, Nieber K, Oppenheimer NJ, Hauschildt S (2004) Extracellular NAD+ regulates intracellular free calcium concentration in human monocytes. Biochem J 382: 849-856.
39. MacIntyre JP, Pope BL (1991) The involvement of protein kinase C, calcium, and 5-lipoxygenase in the production of tumor necrosis factor by a cloned interleukin-3 dependent cell line with natural cytotoxic activity. Int J Immunopharmacol 13: 175-184.
40. Nadra I, Mason JC, Philippidis P, Florey O, Smythe CD, et al. (2005) Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways. A vicious cycle of inflammation and arterial calcification? Circ Res 96: 1248-1256.
41. Wheeler AP, Bernard GR (2007) Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 9572: 1553-1564.
42. Ware LB, Matthay MA (2000) The acute respiratory distress syndrome. N Engl J Med 342: 1334-1349.
43. Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, et al. (2003) Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 167: 1027-1035.
44. Frank JA, Parsons PE, Matthay MA (2006) Pathogenetic significance of biological markers of ventilator-associated lung injury in experimental and clinical studies. Chest 130: 1906-1914.
45. Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, et al. (2005) Pre-Bcell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res 70: 142-151.
46. Kendal-Wright CE, Hubbard D, Bryant-Greenwood GD (2008) Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor (PBEF/visfatin) expression and protects them from apoptosis. Placenta 29: 255-265.
47. Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, et al. (2007) TNFalpha alters visfatin and adiponectin levels in human fat. Horm Metab Res 39: 250-255.
48. Williams MR, Kataoka N, Sakurai Y, Powers CM, Eskin SG, et al. (2008) Gene expression of endothelial cells due to interleukin-1 beta stimulation and neutrophil transmigration. Endothelium 15: 73-165.
49. Patrone L, Damore MA, Lee MB, Malone CS, Wall R (2002) Genes expressed during the IFN gamma-induced maturation of pre-B cells. Mol Immunol 38: 597-606.
50. Kendal CE, Bryant-Greenwood GD (2007) Pre-B-cell colony-enhancing factor [PBEF/Visfatin] gene expression is modulated by NF-kappa B and AP-1 in human amniotic epithelial cells. Placenta 28: 305-14.
51. Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, et al. (2006) Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 54: 2084-2095.
52. Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, et al. (2006) Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 580: 4105-4113.
53. Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, et al. (2009) NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD (+)-sirtuin-1-dependent pathway. Nat Med 15: 151-158.
54. Van Gool F, Gallí M, Gueydan C, Kruys V, Prevot PP, et al. (2009) Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuindependent manner. Nat Med 15: 206-210.
55. Adya R, Tan BK, Chen J, Randeva HS (2008) Pre-B cell colony enhancing factor [PBEF]/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 205: 113-119.
56. Shen CJ, Tsai EM, Lee JN, Chen YL, Lee CH, et al. (2010) The concentrations of visfatin in the follicular fluids of women undergoing controlled ovarian stimulation are correlated to the number of oocytes retrieved. Ferti l Steril 93: 1844-1850.
57. Liu SW, Qiao SB, Yuan JS, Liu DQ (2009) Visfatin Stimulates Production of Monocyte Chemotactic Protein-1 and Interleukin-6 in Human Vein Umbilical Endothelial Cells. Horm Metab Res 41: 281-286.
58. Kim SR, Bae YH, Bae SK, Choi KS, Yoon KH, et al. (2008) Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 1783: 886-895.
59. Adya R, Tan BK, Chen J, Randeva HS (2008) Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 31: 758-760.
60. Adya R, Tan BK, Punn A, Chen J, Randeva HS (2008) Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 78: 356-365.
61. Kim SR, Bae SK, Choi KS, Park SY, Jun HO, et al. (2007) Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 357: 150-156.
62. Bae YH, Bae MK, Kim SR, Lee JH, Wee HJ, et al. (2009) Upregulation of fibroblast growth factor-2 by visfatin that promotes endothelial angiogenesis. Biochem Biophys Res Commun 379: 206-211.
63. Li Y, Zhang Y, Dorweiler B, Cui D, Wang T, et al. (2008) Extracellular NAMPT promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 283: 34833-34843.
64. Luk T, Malam Z, Marshall JC (2008) Pre-B cell colony-enhancing factor [PBEF]/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83: 804-816.
65. Sasaki Y, Araki T, Milbrandt J (2006) Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci 26: 8484-8491.
66. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, et al. (2009) Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 119: 524-530.
67. Pillai JB, Isbatan A, Imai S, Gupta MP (2005) Poly(ADP-ribos) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J Biol Chem 280: 43121-43130.
68. Yang H, Yang T, Baur JA, Perez E, Matsui T, et al. (2007) Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell 130: 1095-1107.
69. Yang H, Lavu S, Sinclair DA (2006) NAMPT/PBEF/Visfatin: a regulator of mammalian health and longevity? Exp Gerontol 41: 718-726.
70. + metabolism in health and disease. Trends Biochem Sci 32: 12-19.
71. Khan JA, Forouhar F, Tao X, Tong L (2007) Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets 11: 695-705.
72. Glass CK, Witztum JL (2001) Atherosclerosis: the road ahead. Cell 104: 503-516.
73. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, et al. (2007) Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115: 972-980.
74. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y et al. (2008) Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 69: 878-884.
75. Cheng KH, Chu CS, Lee KT, Lin TH, Hsieh CC, et al. (2008) Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes (Lond) 32: 268-274.
76. Hufton SE, Moerkerk PT, Brandwijk R, de Bruïne AP, Arends JW et al. (1999) A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 463: 77-82.
77. Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruïne AP, Arends JW, et al. (2002) Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer 101: 118-127.
78. Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, et al. (2008) PBEF1/NAmPRTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther 7: 663-668.
79. Hasmann M, Schemainda I (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63: 7436-7442.
80. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, et al. (2005) Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 11: 3503-3513.
81. Drevs J, Loser R, Rattel B, Esser N (2003) Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Re 23: 4853-4858.
82. Fulda S (2009) Tumor resistance to apoptosis. Int J Cancer 124: 511-515.
83. Ying W (2008) NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 10: 179-206.
84. Chamberlain MC (2008) Antiangiogenesis: biology and utility in the treatment of gliomas. Expert Rev Neurother 8: 1419-1423.
85. Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, et al. (2008) Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight. J Perinat Med 37: 218-231.
86. Hallschmid M, Randeva H, Tan BK, Kern W, Lehnert H (2008) Relationship of Cerebrospinal Fluid Visfatin [PBEF/NAMPT] Levels to Adiposity in Humans. Diabetes 58: 637-640.
87. Liang Y, Xu XM, Wang HS, Wang PW (2008) Correlation between the expression of gastrocolic omentum visfatin mRNA and gestational diabetes mellitus. Zhonghua Fu Chan Ke Za Zhi 43: 824-827.
88. Ziegelmeier M, Bachmann A, Seeger J, Lossner U, Kratzsch J, et al. (2008) Adipokines influencing metabolic and cardiovascular disease are differentially regulated in maintenance hemodialysis. Metabolism 57: 1414-1421.
89. Retnakaran R, Youn BS, Liu Y, Hanley AJ, Lee NS, et al. (2008) Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 69: 885-893.
90. Botella-Carretero JI, Luque-Ramírez M, Alvarez-Blasco F, Peromingo R, San Millán JL et al. (2008) The increase in serum visfatin after bariatric surgery in morbidly obese women is modulated by weight loss, waist circumference, and presence or absence of diabetes before surgery. Obes Surg 18: 1000-1006.
91. Alghasham AA, Barakat YA (2008) Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy. Saudi Med J 29: 185-192.
92. Sandeep S, Velmurugan K, Deepa R, Mohan V (2007) Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 56: 565-570.
93. Lewandowski KC, Stojanovic N, Press M, Tuck SM, Szosland K, et al. (2007) Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 50: 1033-1037.
94. Fernández-Real JM, Moreno JM, Chico B, López-Bermejo A, Ricart, W. (2007) Circulating visfatin is associated with parameters of iron metabolism in subjects with altered glucose tolerance. Diabetes Care 30: 616-621.
95. Dogru T, Sonmez A, Tasci I, Bozoglu E, Yilmaz MI, et al. (2007) Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract76: 24-29.
96. Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, et al. (2006) Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond) 110: 605-609.
97. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, et al. (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91: 295-299.
98. Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, et al. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54: 2911-2916.
99. Haider DG, Pleiner J, Francesconi M, Wiesinger GF, Muller M et al. (2006) Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab 91: 4702-4704.
100. Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, et al. (2006) Serum visfatin increases with progressive ß-cell deterioration. Diabetes 55: 2871-2875.
101. Akturk M, Altinova AE, Mert I, Buyukkagnici U, Sargin A, et al. (2008) Visfatin concentration is decreased in women with gestational diabetes mellitus in the third trimester. J Endocrinol Invest 31: 610-613.
102. Kato A, Odamaki M, Ishida J, Hishida A (2009) Relationship between serum pre-B cell colony-enhancing factor/visfatin and atherosclerotic parameters in chronic hemodialysis patients. Am J Nephrol 29: 31-35.
103. Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, et al. (2006) The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabet Med 23: 967-973.
104. Palin MF, Labrecque B, Beaudry D, Mayhue M, Bordignon V et al. (2008) Visfatin expression is not associated with adipose tissue abundance in the porcine model. Domest Anim Endocrinol 35: 58-73.
105. Tsiotra PC, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, et al. (2007) Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women. Horm Metab Res 39: 758-763.
106. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J et al. (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 92: 4783-4791.
107. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T (2007) Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 56: 451-458.
108. Chan TF, Chen YL, Lee CH, Chou FH, Wu LC, et al. (2006) Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig 13: 364-367.
109. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, et al. (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 91: 3165-3170.
110. Körner A, Garten A, Blüher M, Tauscher R, Kratzsch J et al. (2007) Molecular characteristics of serum visfatin and differential detection by immunoassays. J Clin Endocrinol Metab 92: 4783-4791.
111. Xie H, Tang SY, Luo XH, Huang J, Cui RR, et al. (2007) Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 80: 201-210.
112. Imai SI (2009) The NAD World: A New Systemic Regulatory Network for Metabolism and Aging-Sirt1, Systemic NAD Biosynthesis, and Their Importance. Cell Biochem Biophys 53: 65-74.
113. Brema I, Hatunic M, Finucane F, Burns N, Nolan JJ, et al. (2008) Plasma visfatin is reduced after aerobic exercise in early onset type 2 diabetes mellitus. Diabetes Obes Metab 10: 600-602.
114. Storka A, Vojtassakova E, Mueller M, Kapiotis S, Haider DG, et al. (2008) Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 38: 820-826.
115. Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, et al. (2005) Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun 336: 747-753.
116. Choi KC, Lee SY, Yoo HJ, Ryu OH, Lee KW, et al. (2007) Effect of PPAR-delta agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes. Biochem Biophys Res Commun 357: 62-67.
117. Zhou H, Yang X, Wang NL, Zhang YO, Cai GP (2007) Macrostemonoside A promotes visfatin expression in 3T3-L1 cells. Biol Pharm Bull 30: 279-283.
118. Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, Gogg S, Jansson PA, et al. (2006) Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J Clin Endocrinol Metab 91: 1181-1184.
119. Pfützner A, Marx N, Walcher D, Löbig M, Seidel D et al. (2008) Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease. Clin Lab 54: 237-241.
120. Erdem G, Dogrum T, Tasci I, Bozoglu E, Muhsiroglu O, et al. (2008) The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus. Diabetes Res Clin Pract 82: 214-218.
121. Zhang YY, Gottardo L, Thompson R, Powers C, Nolan D, et al. (2006) A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 14: 2119-2126.
122. Sun G, Bishop J, Khalili S, Vasdev S, Gill V, et al. (2007) Serum visfatin concentrations are positively correlated with serum triacylglycerols and downregulated by overfeeding in healthy young men. Am J Clin Nutr 85: 399-404.
123. Landré-Beauvais AJ (2001) The first description of rheumatoid arthritis. Unabridged text of the doctoral dissertation presented in 1800. Joint Bone Spine 68: 130-143.
124. Otero M, Lago R, Gomez R, Lago F, Dieguez C, et al. (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65: 1198-1201.
125. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, et al. (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56: 2829-2839.
126. Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, et al. (2008) Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 3: e2267.
127. Liu P, Li H, Cepeda J, Xia Y, Kempf JA, et al. (2009) Regulation of inflammatory cytokine expression in pulmonary epithelial cells by pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism. J Biol Chem 284: 27344-27351.